2021中期報告INTERIM REPORT 財務摘要FINANCIAL HIGHLIGHTS目錄Contents公司資料CORPORATE INFORMATION管理層討論及分析MANAGEMENT DISCUSSION AND ANALYSIS其他資料OTHER INFORMATION合併資產負債表CONSOLIDATED BALANCE SHEET合併利潤表CONSOLIDATED INCOME STATEMENT合併股東權益變動表CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY合併現金流量表CONSOLIDATED STATEMENT OF CASH FLOW母公司資產負債表BALANCE SHEET OF THE PARENT COMPANY母公司利潤表INCOME STATEMENT OF THE PARENT COMPANY母公司股東權益變動表STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY OF THE PARENT COMPANY母公司現金流量表STATEMENT OF CASH FLOW OF THE PARENT COMPANY未經審核中期財務報表附註NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS001033004030038041002035022036032039042 - 001 -財務狀況 Financial Position於2021年6月30日人民幣千元（未經審核）As at 30 June 2021RMB'000 (Unaudited)於2020年12月31日人民幣千元（經審核）As a 31 December 2020RMB'000 (Audited)變動（%）Change(%)總資產 Total assets2,753,721 2,799,403 -1.63總負債 Total liabilities2,246,810 2,296,854 -2.18股東權益 Total equity506,910 502,549 0.87每股淨資產 （以每股人民幣元列示）Net assets per share (expressed in RMB per share)4.6936 4.6532 0.87業績 Results截至 6 月 30 日止六個月Six months ended 30 June變動（%）Change (%)2021 年人民幣千元（未經審核）2021RMB'000 (Unaudited)2020 年人民幣千元（未經審核）2020RMB'000 (Unaudited)營業收入 Operating revenue1,993,014 1,860,759 7.11利潤總額 Total profit34,530 41,746 -17.28歸屬於母公司股東的淨利潤 Net profit attributable to the shareholders of parent company25,961 30,873 -15.91基本及稀釋每股收益 （以每股人民幣元列示）Basic and diluted earnings per share (expressed in RMB per share)0.2404 0.2859 -15.91財務摘要 FINANCIAL HIGHLIGHTS INTERIM REPORT中期報告2021- 002 -公司資料* 董事執行董事姚創龍鄭玉燕林志雄非執行董事李偉生獨立非執行董事尹智偉周濤關鍵（又稱關蘇哲）* 監事張玲鄭禧玥林志杰* 公司秘書林志雄* 審核委員會尹智偉（主席）周濤關鍵（又稱關蘇哲）* 提名委員會周濤（主席）姚創龍關鍵（又稱關蘇哲）* 薪酬委員會周濤（主席）尹智偉林志雄* 風險管理委員會姚創龍（主席）林志雄尹智偉CORPORATE INFORMATION* DIRECTORSExecutive DirectorsYao ChuanglongZheng YuyanLin ZhixiongNon-executive DirectorLi WeishengIndependent Non-executive DirectorsWan Chi Wai AnthonyZhou TaoGuan Jian (also known as Guan Suzhe)* SUPERVISORSZhang LingZheng XiyueLin Zhijie* COMPANY SECRETARYLin Zhixiong* AUDIT COMMITTEEWan Chi Wai Anthony (Chairman)Zhou TaoGuan Jian (also known as Guan Suzhe)* NOMINATION COMMITTEEZhou Tao (Chairman)Yao ChuanglongGuan Jian (also known as Guan Suzhe)* REMUNERATION COMMITTEEZhou Tao (Chairman)Wan Chi Wai AnthonyLin Zhixiong* RISK MANAGEMENT COMMITTEEYao Chuanglong (Chairman)Lin ZhixiongWan Chi Wai Anthony - 003 -* 戰略發展委員會姚創龍（主席）鄭玉燕周濤* 授權代表鄭玉燕林志雄* 核數師信永中和會計師事務所（特殊普通合夥）* 法律顧問鍾氏律師事務所與德恒律師事務所聯營（香港法律）廣東信達律師事務所（中國法律）* 註冊辦公室及總部中國廣東省汕頭市龍湖區嵩山北路 235號* 香港主要營業地點香港灣仔皇后大道東 248 號大新金融中心 40 樓* 主要往來銀行廣發銀行股份有限公司（汕頭分行）中國工商銀行股份有限公司（汕頭分行）* H 股證券登記處香港中央證券登記有限公司香港灣仔皇后大道東 183 號合和中心 17 樓 1712-1716 號舖* 公司網站www.chmyy.com* 股份代號2289.HK* STRATEGIC DEVELOPMENT COMMITTEEYao Chuanglong (Chairman)Zheng YuyanZhou Tao* AUTHORISED REPRESENTATIVESZheng YuyanLin Zhixiong* AUDITORShineWing Certified Public Accountants (Special General Partnership)* LEGAL ADVISERSChungs Lawyers in association with DeHeng Law Offices(as to Hong Kong laws)Shu Jin Law Firm (as to PRC laws)* REGISTERED OFFICE AND HEADQUARTERSNo. 235, Song Shan North Road, Longhu District,Shantou City, Guangdong Province, PRC* PRINCIPAL PLACE OF BUSINESS IN HONG KONG40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road East,Wanchai, Hong Kong* PRINCIPAL BANKSChina Guangfa Bank Co., Ltd. (Shantou Branch)Industrial and Commercial Bank of China Limited (Shantou Branch)* H SHARE REGISTRARComputershare Hong Kong Investor Services LimitedShops 1712-1716, 17th Floor Hopewell Centre,183 Queen's Road East, Wanchai, Hong Kong* COMPANY WEBSITEwww.chmyy.com* STOCK CODE2289.HK INTERIM REPORT中期報告2021- 004 -* 行業概覽在「健康中國」戰略、「互聯網+醫療健康」、集採擴面、醫保支付基金等醫改新政的疊加和聯動效應作用下，借助「互聯網+藥品流通」、大數據時代的新技術、新動能進一步賦能，藥品流通行業生態格局將得到重塑，實現高質量發展。同時，在強監管的環境下疊加政策效應，全國和區域性藥品批發企業通過併購重組、強強聯合，擴大市場覆蓋率，藥品流通行業市場集中度不斷提升。醫保制度逐步健全，藥品流通市場化更進一步2021年4月22日國務院辦公廳印發《關於建立健全職工基本醫療保險門診共濟保障機制的指導意見》（「《意見》」），提出：逐步將多發病、常見病的門診費用納入統籌支付範圍，覆蓋職工醫保全體參保人員。支持參保人員持外配處方在定點零售藥店結算和配藥。《意見》進一步提出：門診統籌資金可用於支付參保人員本人及其配偶、父母、子女在定點醫療機構就醫以及在定點零售藥店購買藥品、醫療器械、醫用耗材所發生的費用，從而將醫保保障範圍從參保人本人擴展到其家庭成員，增加了勞動者家庭的醫療保障程度，提高了社會福利水平。* INDUSTRY OVERVIEWUnder the combined and interactive effects of new medical reform policies including the “Healthy China” initiative, “Internet+ Healthcare”, increased adoption of centralised procurement, and the introduction of medical insurance payment fund, the ecology of pharmaceutical distribution industry will be reshaped and experiences high-quality development through further empowerment from new technologies and new drivers in the era of big data and “Internet+ Pharmaceutical Distribution”. Meanwhile, restricted by stronger supervision and policies, national and regional pharmaceutical wholesalers expand their market coverage by means of merger and acquisition, reorganisation, and alliance between powerful enterprises, leading to an increasing market concentration in the pharmaceutical distribution industry.Gradually improving medical insurance system and further liberalising the pharmaceutical di